Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Cross-Sectional Study

Adenovirus 36 Coinfection in People Living with HIV and its Impact on Lipohypertrophy

Author(s): Helena Caetano Gonçalves e Silva, Jaime Fernandes da Silva, Ana Carolina Lobor Cancelier, Daisson José Trevisol, Thiago Armando Mamôru Sakae, Richard L. Atkinson and Fabiana Armando Schuelter-Trevisol*

Volume 21, Issue 2, 2023

Published on: 22 May, 2023

Page: [140 - 146] Pages: 7

DOI: 10.2174/1570162X21666230420090756

Price: $65

Abstract

Background: Previous studies have implicated human adenovirus 36 (Adv36) as a potential contributor to overweight and obesity. People living with HIV have an altered body composition compared to healthy individuals. There is still no evidence to confirm the relationship of Adv36 as one of the causes of lipohypertrophy. The main objective of this study was to verify the viral Adv36 infection as a factor associated with the presence of lipohypertrophy in HIV-infected individuals.

Methods: A case-control study on people with HIV treated at a specialized public health service in southern Brazil. Subjects underwent interviews, diagnostic tests, and anthropometry to determine lipodystrophy and its classification. Demographic and clinical data were examined to investigate the presence of Adv36. The cases were participants with lipohypertrophy, and the controls were eutrophic participants.

Results: 101 participants were included (38 cases and 63 controls), and the frequency of Adv36 infection was 10.9%. There was a statistically significant association between lipohypertrophy and the female sex (p < 0.001), and a trend for the presence of Adv36 (p = 0.059) and lipohypertrophy. After adjustment for confounders, Adv36 has not considered an independent risk factor for lipohypertrophy. Lower levels of glucose were associated with Adv36 infection.

Conclusion: There was a significant association between lipohypertrophy and the female sex, and no association with lipohypertrophy and Adv36, perhaps due to the small sample size.

Keywords: Obesity, lipodystrophy, HIV, adenovirus, human, acquired immunodeficiency syndrome.

« Previous Next »
Graphical Abstract

[1]
Means AR, Risher KA, Ujeneza EL, Maposa I, Nondi J, Bellan SE. Impact of age and sex on CD4+ cell count trajectories following treatment initiation: An analysis of the tanzanian hIV treatment database. PLoS One 2016; 11(10): e0164148.
[http://dx.doi.org/10.1371/journal.pone.0164148] [PMID: 27716818]
[2]
Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356(9239): 1423-30.
[http://dx.doi.org/10.1016/S0140-6736(00)02854-3] [PMID: 11052597]
[3]
R Alencastro P, Wolf FH, Schuelter-Trevisol F, Ikeda ML, Brandão ABM, Barcellos NT, et al. Characteristics associated to lipodystrophy syndrome among HIV-infected patients naïve and on antiretroviral treatment. J AIDS Clin Res 2012; 3(9): 1-9.
[http://dx.doi.org/10.4172/2155-6113.1000182]
[4]
Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep 2008; 5(3): 140-9.
[http://dx.doi.org/10.1007/s11904-008-0022-4] [PMID: 18627663]
[5]
Baril JG, Junod P, LeBlanc R, et al. HIV-associated lipodystrophy syndrome: A review of clinical aspects. Can J Infect Dis Med Microbiol 2005; 16(4): 233-43.
[http://dx.doi.org/10.1155/2005/303141] [PMID: 18159551]
[6]
Couto RD, Oliveira DPR, Macêdo APA, dos Santos GM. Dyslipidemia secondary to the use of haart in adults: Systematic review. Curr Drug Res Rev 2022; 14(3): 239-46.
[http://dx.doi.org/10.2174/2589977514666220519165549] [PMID: 35619289]
[7]
Na HN, Kim H, Nam JH. Prophylactic and therapeutic vaccines for obesity. Clin Exp Vaccine Res 2014; 3(1): 37-41.
[http://dx.doi.org/10.7774/cevr.2014.3.1.37] [PMID: 24427761]
[8]
Della Justina LB, Trevisol DJ, Schuelter-Trevisol F. Prevalence of hiv-associated lipodystrophy in Brazil: A systematic review of the literature. J AIDS Clin Res 2015; 5: 9.
[9]
Santos AP, Machado DRL, Schwingel A, et al. Anthropometric cutoff points to identify lipodystrophy characteristics in people living with HIV/AIDS: An observational study. Nutr Hosp 2019; 36(6): 1315-23.
[http://dx.doi.org/10.20960/nh.02715] [PMID: 31657611]
[10]
Soares FM, Costa IM. HIV-Associated facial lipoatrophy: From the advent to current knowledge. An Bras Dermatol 2011; 86(5): 843-62.
[http://dx.doi.org/10.1590/S0365-05962011000500001] [PMID: 22147023]
[11]
Atkinson RL, Dhurandhar NV, Allison DB, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes 2005; 29(3): 281-6.
[http://dx.doi.org/10.1038/sj.ijo.0802830] [PMID: 15611785]
[12]
Atkinson RL. Viruses as an etiology of obesity. Mayo Clin Proc 2007; 82(10): 1192-8.
[http://dx.doi.org/10.4065/82.10.1192] [PMID: 17908526]
[13]
da Silva Fernandes J, Schuelter-Trevisol F, Cancelier ACL, et al. Adenovirus 36 prevalence and association with human obesity: A systematic review. Int J Obes 2021; 45(6): 1342-56.
[http://dx.doi.org/10.1038/s41366-021-00805-6] [PMID: 33753885]
[14]
Ponterio E, Gnessi L. Adenovirus 36 and obesity: An overview. Viruses 2015; 7(7): 3719-40.
[http://dx.doi.org/10.3390/v7072787] [PMID: 26184280]
[15]
Cancelier ACL, Rezin GT, Fernandes J, et al. Adenovirus-36 as one of the causes of obesity: The review of the pathophysiology. Nutr Res 2021; 86: 60-7.
[http://dx.doi.org/10.1016/j.nutres.2020.12.004] [PMID: 33551256]
[16]
Cancelier ACL, Schuelter-Trevisol F, Trevisol DJ, Atkinson RL. Adenovirus 36 infection and obesity risk: Current understanding and future therapeutic strategies. Expert Rev Endocrinol Metab 2022; 17(2): 143-52.
[http://dx.doi.org/10.1080/17446651.2022.2044303] [PMID: 35255768]
[17]
Florindo AA, Latorre MRDO, Santos ECM, Borelli A, Rocha MS, Segurado AAC. Validation of methods of estimation of body fat in carriers of HIV/Aids. Rev Saude Publica 2004; 38(5): 643-9.
[http://dx.doi.org/10.1590/S0034-89102004000500005] [PMID: 15499434]
[18]
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: The AIDS Clinical trials group longitudinal linked randomized trials (ALLRT) cohort and NHANES. PLoS One 2013; 8(6): e65306.
[http://dx.doi.org/10.1371/journal.pone.0065306] [PMID: 23755215]
[19]
Ponterio E, Cangemi R, Mariani S, et al. Adenovirus 36 DNA in human adipose tissue. Int J Obes 2015; 39(12): 1761-4.
[http://dx.doi.org/10.1038/ijo.2015.163] [PMID: 26293231]
[20]
Na H-N, Hong Y-M, Kim J, Kim H-K, Jo I, Nam J-H. Association between human adenovirus-36 and lipid disorders in Korean schoolchildren. Int J Obes 2010; 34(1): 89-93.
[http://dx.doi.org/10.1038/ijo.2009.207] [PMID: 19823186]
[21]
Aldhoon-Hainerová I, Zamrazilová H, Atkinson RL, et al. Clinical and laboratory characteristics of 1179 Czech adolescents evaluated for antibodies to human adenovirus 36. Int J Obes 2014; 38(2): 285-91.
[http://dx.doi.org/10.1038/ijo.2013.72] [PMID: 23732656]
[22]
Vander Wal JS, Huelsing J, Dubuisson O, Dhurandhar NV. An observational study of the association between adenovirus 36 antibody status and weight loss among youth. Obes Facts 2013; 6(3): 269-78.
[http://dx.doi.org/10.1159/000353109] [PMID: 23751249]
[23]
Almgren M, Atkinson RL, Hilding A, et al. Human adenovirus-36 is uncommon in type 2 diabetes and is associated with increased insulin sensitivity in adults in Sweden. Ann Med 2014; 46(7): 539-46.
[http://dx.doi.org/10.3109/07853890.2014.935469] [PMID: 25045929]
[24]
Sapunar J, Fonseca L, Molina V, et al. Adenovirus 36 seropositivity is related to obesity risk, glycemic control, and leptin levels in Chilean subjects. Int J Obes 2020; 44(1): 159-66.
[http://dx.doi.org/10.1038/s41366-019-0321-4] [PMID: 30659258]
[25]
Foulds HJA, Bredin SSD, Warburton DER. The prevalence of overweight and obesity in British Columbian Aboriginal adults. Obes Rev 2011; 12(5): e4-e11.
[http://dx.doi.org/10.1111/j.1467-789X.2010.00844.x] [PMID: 21382152]
[26]
Power ML, Schulkin J. Sex differences in fat storage, fat metabolism, and the health risks from obesity: Possible evolutionary origins. Br J Nutr 2008; 99(5): 931-40.
[http://dx.doi.org/10.1017/S0007114507853347] [PMID: 17977473]
[27]
Diehl LA, Dias JR, Paes ACS, et al. Prevalence of lipodystrophy associated with HIV in Brazilian ambulatory patients: Relationship with metabolic syndrome and cardiovascular risk factors. Arq Bras Endocrinol Metabol 2008; 52(4): 658-67.
[http://dx.doi.org/10.1590/S0004-27302008000400012] [PMID: 18604379]
[28]
Valente AMM, Reis AF, Machado DM, Succi RCM, Chacra AR. Metabolic alterations of lipodystrophic syndrome of HIV. Arq Bras Endocrinol Metabol 2005; 49(6): 871-81.
[http://dx.doi.org/10.1590/S0004-27302005000600004] [PMID: 16544008]
[29]
Mariz CA, Albuquerque MFPM, Ximenes RAA, et al. Body mass index in individuals with HIV infection and factors associated with thinness and overweight/obesity. Cad Saude Publica 2011; 27(10): 1997-2008.
[http://dx.doi.org/10.1590/S0102-311X2011001000013] [PMID: 22031204]
[30]
Kroll AF, Sprinz E, Leal SC, Labrêa MG, Setúbal S. Prevalence of obesity and cardiovascular risk in patients with HIV/AIDS in Porto Alegre, Brazil. Arq Bras Endocrinol Metabol 2012; 56(2): 137-41.
[http://dx.doi.org/10.1590/S0004-27302012000200007] [PMID: 22584567]
[31]
Kato I, Tumaini B, Pallangyo K. Prevalence of non-communicable diseases among individuals with HIV infection by antiretroviral therapy status in Dar es Salaam, Tanzania. PLoS One 2020; 15(7): e0235542.
[http://dx.doi.org/10.1371/journal.pone.0235542] [PMID: 32645054]
[32]
van Heerden A, Barnabas RV, Norris SA, Micklesfield LK, van Rooyen H, Celum C. High prevalence of HIV and non-communicable disease (NCD) risk factors in rural KwaZulu-Natal, South Africa. J Int AIDS Soc 2017; 20(2): e25012.
[http://dx.doi.org/10.1002/jia2.25012] [PMID: 29064168]
[33]
Peddibhotla S, Hegde V, Akheruzzaman M, Dhurandhar NV. E4orf1 protein reduces the need for endogenous insulin. Nutr Diabetes 2019; 9(1): 17.
[http://dx.doi.org/10.1038/s41387-019-0085-x] [PMID: 31127081]

Rights & Permissions Print Cite
Article Metrics
21
2
© 2024 Bentham Science Publishers | Privacy Policy